{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:45:17Z","timestamp":1786488317384,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jaad.2024.07.1473","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T13:58:01Z","timestamp":1722175081000},"page":"889-895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interleukin 23 versus interleukin 12\/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network"],"prefix":"10.1016","volume":"91","author":[{"given":"Sung Huang Laurent","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Ping","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2024.07.1473_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2024.07.1473_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1468-3083.2010.03730.x","article-title":"Economic burden of comorbidities in patients with psoriasis is substantial","volume":"25","author":"Kimball","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2024.07.1473_bib3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and\u00a0the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.07.1473_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/1756-185X.14298","article-title":"Depression in psoriatic arthritis: related to socio-demographics, comorbid loads or disease activity?","volume":"25","author":"Lai","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.07.1473_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.07.1473_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1756-185X.14474","article-title":"Current treatment strategies and recommendations in psoriatic arthritis","volume":"26","author":"Kao","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.07.1473_bib7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/1756-185X.14805","article-title":"Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis","volume":"26","author":"Lu","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2024.07.1473_bib8","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s13555-023-01025-8","article-title":"Prevalence of musculoskeletal symptoms in patients with psoriasis and predictors associated with the development of psoriatic arthritis: retrospective analysis of a US claims database","volume":"13","author":"Merola","year":"2023","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2024.07.1473_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jaad.2024.07.1473_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/exd.13676","article-title":"Inhibition of interleukin-12 and\/or interleukin-23 for the treatment of psoriasis: what is the evidence for an effect on malignancy?","volume":"27","author":"Ergen","year":"2018","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.07.1473_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.jaad.2024.07.1473_bib12","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R\u03b21 and a novel cytokine receptor subunit, IL-23R1","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2024.07.1473_bib13","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jaad.2024.07.1473_bib14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/1756-185X.13879","article-title":"Psoriatic arthritis: a systematic review of non-HLA genetic studies and important signaling pathways","volume":"23","author":"Chen","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2024.07.1473_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.220309","article-title":"Management of axial disease in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Lubrano","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2024.07.1473_bib16","author":"Mease"},{"key":"10.1016\/j.jaad.2024.07.1473_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/CCID.S402183","article-title":"Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study","volume":"16","author":"Ruggiero","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.07.1473_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/1060028019885836","article-title":"Risankizumab for the treatment of moderate to severe plaque psoriasis","volume":"54","author":"Li","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.jaad.2024.07.1473_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol Res"},{"issue":"5","key":"10.1016\/j.jaad.2024.07.1473_bib20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/1756-185X.14663","article-title":"Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: a pilot prospective real-world study","volume":"26","author":"Ak","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.07.1473_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFi-na\u00efve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jaad.2024.07.1473_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2021-221255","article-title":"Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?","volume":"81","author":"McGonagle","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2024.07.1473_bib23","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.07.1473_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.41619","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study","volume":"73","author":"D'Silva","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.07.1473_bib25","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1111\/jdv.19328","article-title":"Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors \u2013 a population-based study","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2024.07.1473_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"1","key":"10.1016\/j.jaad.2024.07.1473_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/187152809787582507","article-title":"The IL-12 family of cytokines in infection, inflammation and autoimmune disorders","volume":"8","author":"Gee","year":"2009","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"12","key":"10.1016\/j.jaad.2024.07.1473_bib28","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"issue":"5 Suppl 93","key":"10.1016\/j.jaad.2024.07.1473_bib29","first-page":"S115","article-title":"Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis","volume":"33","author":"Johnsson","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.07.1473_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.qco.0000224818.42729.67","article-title":"Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy","volume":"19","author":"Bowman","year":"2006","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"10.1016\/j.jaad.2024.07.1473_bib31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/eji.200324038","article-title":"The role of interleukin-12 in human infectious diseases: only a faint signature","volume":"33","author":"Fieschi","year":"2003","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2024.07.1473_bib32","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jaad.2008.08.034","article-title":"Potential misclassification of psoriasis patients in electronic databases","volume":"59","author":"Icen","year":"2008","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224025556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224025556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T07:22:20Z","timestamp":1732864940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224025556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0190962224025556"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.07.1473","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin 23 versus interleukin 12\/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.07.1473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}